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TLE Transvenous lead extraction ICD Implantable cardioverter-defibrillator 
ROC Receiver operator characteristic NS Not significant 
LVEF Left ventricular ejection fraction OR Odds ratio 
UK United Kingdom CRT Cardiac resynchronization therapy 
LLD Lead locking device LV Left ventricular 
CI Confidence interval CABG Coronary artery bypass graft  





Background: Transvenous lead extraction (TLE) may be performed by superior approach using the original 
implant vein or via a femoral approach, however, limited comparative data exists. We compare outcomes 
between femoral versus non-femoral TLE approaches and determine predictors of bailout transfemoral lead 
extraction in patients undergoing initial TLE via the original implant vein by a superior approach. 
 45 
Methods: All consecutive TLEs between October 2000 and March 2018 were prospectively collected 
(n=1052). Patients were dichotomized into femoral (n=118) and non-femoral (n=934) groups. 
 
Results: Demographics were balanced between femoral vs. non-femoral groups. Patients in the femoral 
group had significantly higher mean lead dwell times (11.69.7 vs. 6.66.6 years, p<0.001), mean number of 50 
leads extracted (2.71.3 vs. 2.01.0, p<0.001), 30-day procedure related major complications (including 
deaths) (8.5% vs. 1.1%, p<0.001) and emergency thoracotomy rates (4.2% vs. 0.7%, p=0.007). All-cause 30-
day mortality rates were similar between groups (3.4% vs. 2.0%, p=0.315). Prolonged lead dwell time and 
increased number of leads extracted were predictive of a bailout transfemoral approach at multivariable 
analysis. 55 
 
Conclusion: Femoral approach TLE is associated with increased risk of 30-day procedure related major 
complications but not 30-day all-cause mortality. Prolonged lead dwell time and increased number of leads 
extracted are independent predictors for bailout transfemoral lead extraction. Such patients should be 
considered high risk of major complications and performed by high-volume lead extraction centres with 60 
experience in multiple approaches and techniques including experience with transfemoral lead extraction. 
 
 





Transvenous lead extraction (TLE) is considered the first-line approach when extraction of a transvenous lead 
is indicated and is most commonly performed from the superior approach using the original implant vein.(1,2) 
The femoral approach utilizing snares was often preferred before the advent of powered sheaths,(3–5) 70 
however, operator preference, expertise and availability of powered sheathes now play a role in selecting 
the initial TLE approach, usually favouring the superior approach.(4,6–8) The femoral approach, however, 
remains important as a ‘bailout’ procedure for complex TLE where an initial superior approach via the original 
implant vein is unsuccessful. The femoral approach may also be required as a primary approach in situations 
of intra-vascular (previously cut/abandoned) leads when complete lead extraction is desired in the setting of 75 
systemic infection,  if there is the need for distal support to maintain superior venous access or where a lead 
was implanted via the femoral venous route.(4) The femoral approach, as both a bailout procedure and a 
primary procedure, is therefore an essential but rarely practiced skill in the armamentarium of lead extractors. 
Limited data exist comparing femoral versus non-femoral TLE approaches, however the ELECTRa study 
showed that femoral extraction was associated with a greater than threefold risk of clinical failure and a 80 
similar increased risk of procedure related major complications including death.(2) Prediction of the need for 
bailout extraction procedures is therefore critical in terms of risk stratification and procedural planning of 
TLE. We acknowledge the internal transjugular approach, first described by Bongiorni et al (2000) as an 
alternative bailout procedure where extraction via the original implant vein is unsuccessful, however this is 
not something practiced routinely in our institution and hence does not feature in our analysis.(8,9) We 85 
therefore set out to assess differences in outcomes between femoral versus non-femoral groups and define 




Consecutive patients undergoing TLE at a high-volume UK lead extraction centre between October 2000 and 
March 2018 were prospectively recorded onto a computer registry. Multiple parameters including 
procedural outcomes were incorporated into the registry. The registry collection and analysis were approved 
by the Institutional Review Board of Guy’s and St Thomas’ Hospital. For the current analysis, TLE procedures 
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were dichotomized into ‘femoral’ and ‘non-femoral’ approaches. Excluding the 14 patients that had a primary 95 
femoral approach, we also assessed procedural outcomes and clinical characteristics of the bailout 
transfemoral lead extraction subgroup (n=104). Excluding the 14 patients that had a primary femoral 
approach, we also analyzed predictors of bailout transfemoral lead extraction for the remaining 1038 
patients. Clinical records were reviewed to determine mortality aetiology for patients who died within 30 
days of TLE.  100 
 
Extraction procedure  
Procedures were performed by the same six experienced operators in a cardiac catheter laboratory, hybrid 
laboratory or operating room with immediate onsite cardiothoracic surgical cover as previously 
described.(10–14) The majority of TLEs were undertaken in the cardiac catheterization laboratory with 105 
informal surgical cover. Patients deemed to be higher risk due to factors such as prolonged lead dwell time 
underwent TLE in a dedicated cardiac hybrid laboratory or operating room with a cardiothoracic surgeon 
present. At our centre, patients are currently discussed in an electrophysiology multidisciplinary meeting 
including the presence of transvenous lead extractors, cardiothoracic surgeons, anesthetists and nurse 
specialists. Whilst we currently do not have strict criteria to determine procedure location, patients with one 110 
or more pacemaker lead with a dwell time of 10 years or an ICD lead with a dwell time of 5 years usually 
undergo TLE in the cardiac hybrid laboratory with a surgeon present and the patient’s chest cleaned and 
prepared for emergency thoracotomy. In addition, older patients ( 70 years old), systemic infection 
indication and multiple advanced co-morbidities are typically considered higher risk at our centre and 
performed in the cardiac hybrid laboratory. The preferred initial route was a superior approach via the 115 
original implant vein wherever possible with a subsequent stepwise approach undertaken including the use 
of cross-over tools. Initially manual traction with the aid of a locking stylet (e.g. Liberator Universal Locking 
Stylet, Cook Medical, Leechburg, PA, USA or LLD® Lead locking device, Spectranetics, Colorado Springs, CO, 
USA) was performed. If a lead was not extractable with manual traction, a powered laser (e.g. Excimer laser 
CVX- 300, Spectranetics Colorado Springs, CO, USA) and/or mechanical sheath was used (Tightrail Rotating 120 
dilator sheath, Spectranetics Colorado Springs, CO, USA) and we attempted upsizing the powered sheaths in 
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a step-wise fashion if initially unsuccessful. Laser lead extraction has been in regular use at our centre since 
1998 and therefore throughout the study period. More recently, the Tightrail rotating dilator sheath has been 
in use at our centre. If the superior approach via the original implant vein was unsuccessful despite using a 
stepwise technique including the use of cross-over tools, we employed the femoral work station as the initial 125 
bailout technique. If this was unsuccessful, we then proceeded to use the Needles Eye Snare (Cook Medical, 
Leechburg, PA, USA,)  if there were no free ends to either snare or pull the leads inferiorly. The leads were 
then either fully extracted using the Needles Eye Snare or if there were still free ends, a 20mm or 25mm 
Goose neck snare (Cook Medical, Leechburg, PA, USA,) was employed. Patients underwent transthoracic 
echocardiography post TLE (unless intra-operative transesophageal echocardiography was used) to assess 130 
for hemodynamically significant pericardial collections and valve damage and a chest radiograph.  
 
Definitions 
Renal impairment was defined as an estimated glomerular filtration rate (eGFR) <60 mL/min/1.73m2. The 
Heart Rhythm Society (2009 and 2017)(1,15) consensus documents were used to define procedural 135 
techniques, approaches and outcomes. Safety and efficacy of TLE were calculated by evaluating the rate of 
procedure related major complications and clinical failure rate. Major complication was defined as any 
outcome related to the procedure which was life threatening or resulted in death, an unexpected event that 
caused persistent or significant disability or any event requiring significant surgical intervention to prevent 
any of these outcomes within 30 days of TLE. The association of a major complication or death to the 140 
procedure was defined by two experienced cardiologists. Intra-procedural complications were defined as any 
event related to the performance of the procedure that occurred or became evident from the time the 
patient entered the operating room until the time the patient left the room where the TLE was performed. 
Intra-procedural complications also included complications related to patient preparation, anesthesia and 
incision opening or closing. Post-procedural complications were defined as any event occurring within 30 145 
days after TLE. Clinical failure was assessed for each TLE procedure and was defined as the inability to achieve 
either complete procedural or clinical success, or the development of any permanently disabling 
complication or procedure related death. 
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For the analysis, the ‘femoral’ group included any TLE procedure involving a transfemoral approach. The 
‘non-femoral’ group included all superior TLE procedures via the original implant vein that did not involve a 150 
transfemoral approach. The ‘bailout transfemoral lead extraction’ subgroup included all TLE procedures that 
were unsuccessful from a superior approach via the original implant vein despite the use of a stepwise 
approach using cross-over tools (as outlined in the extraction procedure methods section) and required a 
bailout transfemoral lead extraction approach during the same procedure, regardless of whether the 
procedure was ultimately deemed to be clinically successful or not. There were no lead extractions 155 
performed via the internal transjugular approach. 
 
Statistical analysis 
Discrete data are presented as n values with corresponding percentages in parentheses and continuous data 
as mean ± 1 standard deviation. Categorical variables were compared using Fisher’s exact test. Continuous 160 
data were assessed for normality with the Shapiro-Wilk test where p0.05 was considered normally 
distributed data. Normally distributed data were compared with an independent samples t-test. Non-
normally distributed data were compared using the Wilcoxon signed-rank test. Univariable and multivariable 
binary logistic regression were performed to determine independent predictors of bailout transfemoral 
extraction in the femoral group, excluding the 14 patients that had a primary femoral approach. Variables 165 
found to be statistically significant at univariable analysis, as well as important clinical covariables were used 
as the basis for multivariable analysis, where p≤0.05 was considered statistically significant. All reported 
associations are presented as odds ratio (ORs) with corresponding 95% confidence intervals (CI). Odds ratio 
for continuous variables represents the relative increased risk of endpoint per unit increase (e.g. per one year 
increase in time for lead dwell time). Statistical analysis was performed using SPSS Statistics (IBM Corporation. 170 
Released 2017. IBM Statistical Package for the Social Sciences (SPSS) Statistics for Macintosh, Version 24.0.0.1. 










A total of 1052 TLEs were performed by six different first operators during the study period. Of these, we 
identified 118 TLE procedures performed involving the transfemoral approach (femoral group) and 934 TLE 
procedures performed exclusively via the superior approach using the original implant vein (non-femoral 
group), meaning that a femoral approach was required in 11.2% (118/1052) of all cases. There were 104 
bailout transfemoral cases out of 1038 TLEs (excluding the 14 primary femoral extractions). Therefore, 10% 185 
of cases were unsuccessful from the superior route alone and subsequently required transfemoral 
techniques during the same procedure. 
 
Femoral versus non-femoral group characteristics 
Device and lead characteristics are shown in Table 1 for femoral and non-femoral groups. Demographics 190 
were balanced between the femoral vs. non-femoral groups (Table 2). Patients were of similar age (63.916.3 
vs. 65.614.8, p=0.402), predominantly male (75.4% vs. 73.4%, p=0.739) and had similar mean left ventricular 
ejection fraction (LVEF) (46.7%14.7% vs. 44.0%14.50%, p=0.120). Multiplicity of comorbidities were 
balanced for both groups. Within the femoral group, 44.1% of leads had a dwell time of 10 years and 50% 
had 1 ICD lead extracted. Additionally, 14.4% (17/118) had both a lead dwell time of 10 years and an ICD 195 
lead extracted in the femoral group. Within the non-femoral group, 22.4% (210/934) had a lead dwell time 
of 10 years, 39.9% (373/934) had 1 ICD lead extracted and 6.3% (59/934) had a combination of these 
factors. 
 
Clinical features and procedural characteristics for femoral versus non-femoral groups  200 
Table 3 demonstrates clinical features and procedural characteristics for femoral and non-femoral groups. 
Notably the mean lead dwell time was significantly longer (approximately double) in the femoral group 
(11.6±9.7 years vs. 6.6±6.6 years, p<0.001) as was the mean number of leads extracted per case (2.71.3 vs. 
2.01.0, p<0.001). There was a significantly greater number of patients with positive microbiology in the 
femoral group (51.7% vs. 37.0%, p=0.003) as well as valvular or lead vegetations (18.3% vs. 7.8%, p=0.003). 205 
Powered sheath extraction was more frequently required in the femoral group (76.3% vs. 52.3%, p<0.001). 
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Clinical failure rates were also higher in the femoral group but not significantly different between groups (3.4% 
vs. 1.1%, p=0.064). Notably femoral cases were more likely to be performed in the operating room/hybrid 
laboratory (28.0% vs 0.5%, p<0.001). 
 210 
Complications and mortality for femoral versus non-femoral groups 
Table 3 shows procedural outcomes for femoral versus non-femoral groups. The 30-day procedure related 
major complication rate including procedure related deaths for all cases was 20/1052 (1.9%). Procedure 
related major complications including deaths was significantly higher in the femoral group (10/118, 8.5% vs. 
10/934, 1.1%, p<0.001) and this remained the case when divided into intra-procedural (9/118, 7.6% vs. 9/934, 215 
1.0%, p<0.001) and post-procedural (2/118, 1.7% vs. 1/934, 0.1%, p=0.035) related major complications 
including procedure related deaths. The overall procedure related mortality rate was 3/1052 (0.3%) and was 
similar between the femoral and non-femoral groups (1/118, 0.8% vs. 2/934, 0.2%, p=0.300). This was again 
consistent between the two groups when divided into intra-procedural (0, 0% vs. 1/934, 0.1%, p=NS) and 
post-procedural (1/118, 0.8% vs. 1/934, 0.1%, p=NS) deaths. The overall emergency thoracotomy rate was 220 
12/1052 (1.1%) and was significantly higher in the femoral group (5/118, 4.2%  vs. 7/934, 0.7%, p=0.007). 
Cardiac and vascular avulsion were drivers for procedural related major complications with only 5/11 
proceeding to emergency thoracotomy in the femoral group (4 of these were due to vascular avulsion, 1 due 
to cardiac avulsion). The remaining 1 vascular avulsion (which was of the left subclavian vein causing a 
haemothorax) was managed with pleural drainage & the other 5 cardiac avulsions (causing cardiac 225 
tamponade) were managed with pericardiocentesis. The overall all-cause 30-day major complication rate 
including deaths was 40/1052 (3.8%) and all-cause 30-day mortality was 23/1052 (2.2%). The all-cause 30-
day major complication rate including deaths was significantly higher in the femoral group (13/118, 11.0% 
vs. 27/934, 2.9%, p<0.001), however, the all-cause 30-day mortality rate was similar between femoral and 
non-femoral groups (4/118, 3.4% vs. 19/934, 2.0%, p=0.315) as was the 30-day non-procedure related 230 
mortality rate (3/118, 2.5% vs. 17/934, 1.8%, p=0.483). Table 4 demonstrates that the majority of deaths was 
due to sepsis in both groups. 
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Bailout transfemoral lead extraction demographics 
Patient demographics for the bailout transfemoral lead extraction subgroup are included in Table 5. This 235 
subgroup were predominantly male with a mean age of  63.9 ± 16.1 years and a mean LVEF at time of the 
extraction of 47.0%  14.9%. Over half of the bailout transfemoral lead extraction subgroup had 2 or more 
comorbidities and just over a third had 3 or more comorbidities. 
 
Clinical features and procedural characteristics for the bailout transfemoral group 240 
Table 6 demonstrates clinical features and procedural characteristics for the bailout transfemoral subgroup. 
The mean lead dwell time was 11.8 ± 9.6 years and the mean number of leads extracted per case was 2.8  
1.3. A greater number of patients underwent TLE for local infection and/or erosion indications (41.3%) 
compared to systemic infection indications (15.4%). 
 245 
Complications and mortality for bailout transfemoral lead extraction 
Table 6 shows procedural outcomes for the bailout transfemoral lead extraction subgroup. The 30-day 
procedure related major complication rate including procedure related deaths was 9.6% and the emergency 
thoracotomy rate was 4.8%.  The overall procedure related mortality rate was 1%. The all-cause 30-day major 
complication rate including all deaths was 11.5% and the all-cause 30-day mortality rate was 2.9%. 250 
Furthermore, the 30-day non-procedure related mortality rate was 1.9%. 
 
 
Predictors of bailout transfemoral lead extraction 
We performed binary logistic regression analysis to predict the need for bailout transfemoral lead extraction 255 
on all patients except those that had a primary transfemoral lead extraction (n=1038). Univariable analysis 
showed prolonged lead dwell time, increased number of leads extracted, ICD lead extraction, prior stroke 
and vegetation were associated with requiring bailout transfemoral lead extraction (Figure 1A). Prolonged 
lead dwell time (OR 1.080, 95% CI 1.050-1.112, p<0.001) and increased number of leads extracted (OR 1.766, 
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95% CI 1.407-2.215, p<0.001) remained independent predictors of bailout transfemoral lead extraction at  260 
multivariable analysis (Figure 1B). 
 
Discussion  
We present a detailed analysis on predictors of bailout transfemoral lead extraction and compare outcomes 
between femoral and non-femoral groups.  265 
 
Femoral versus non-femoral groups 
Patients in the femoral group were more likely to have positive microbiology and vegetations present which 
most likely reflects the need for complete removal of leads without leaving residual lead fragments in such 
patients. As expected, the mean lead dwell time was significantly longer in the femoral group (almost double 270 
that of the non-femoral group) since longer lead dwell times are associated with more challenging lead 
extractions due to adhesions which sometimes require a transfemoral approach. Additionally, the mean 
number of leads extracted per case and the use of a powered sheaths were both significantly higher in the 
femoral group which reflects the increased complexity of procedures within this group requiring a 
transfemoral approach.  275 
 
Predictors of bailout transfemoral lead extraction 
Prolonged lead dwell time and increased number of leads extracted should alert clinicians that in such cases, 
bailout femoral extraction may be required to allow necessary pre-procedural planning in terms of surgical 
cover, procedure location and availability of the necessary tools and operator experience to perform bailout 280 
transfemoral lead extraction if required. Although such cases are associated with a higher rate of emergency 
thoracotomy, these are often cases of systemic infection where a superior approach via the original implant 
vein has failed to remove the leads, and there would likely be a need to proceed to surgical extraction to 
achieve clinical success if femoral extraction was not an option. One could argue that without such femoral 
extraction techniques, the need for thoracotomy may in fact be higher to remove infected lead fragments 285 
that could otherwise be removed by femoral snaring. 
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Female gender is generally considered to be a poor prognostic marker as shown in the ELECTRa study (2017) 
where female gender was a predictor of procedure related major complications including deaths as well as 
clinical failure.[Bongiorni et al, EHJ, 2017] The female gender results in the present study differ between the 
univariable (Figure 1A) and multivariable (Figure 1B) binary logistic regression analyses in our cohort. 290 
However, neither results were significant and given the relatively small numbers of female compared to male 
patients in the bailout transfemoral lead extraction group (25/104, 24.0% females vs. 79/104, 76% males) as 
well as other important demographic factors, it’s difficult to draw any firm conclusions and an in-depth 
analysis on gender difference is beyond the scope of the current manuscript. Additionally, prior stroke was 
significant at univariable analysis (Figure 1A) but became non-significant in the multivariable model (Figure 295 
1B). We suspect this most likely reflects an association with other comorbidities rather than represent a new 
finding, however, future detailed analyses may be of interest to explore this futher. We also identified that 
the presence of vegetations was significant at univariable analysis and became non-significant at 
multivariable analysis. The reasons for this are not entirely clear but may be related to the fact that there is 
a requirement to attempt to remove all lead material in the setting of infection whereas in non-infected cases 300 
it may not always be necessary to complete the lead extraction and in such cases leads or lead fragments 
may have been abandoned after a failed superior approach rather than progress to a bailout transfemoral 
procedure. 
  
Comparison with previous studies 305 
Bordachar et al. (2010) studied 101 patients randomized to superior approach TLE using laser (n=50) versus 
transfemoral lead extraction (n=51) as the initial approach at a single centre over 15 months.(3) They 
demonstrated similar major complication rates between the laser extraction group and femoral group with 
no procedure related deaths in either group,(3) however procedure duration and fluoroscopy were 
significantly shorter in the non-femoral group.(3) They also compared non-randomized registries in France 310 
from three TLE centres using superior approach laser extraction (n=218) versus three other centres using 
transfemoral lead extraction (n=138).  There were two procedure-related deaths in the superior extraction 
group (0.9%) versus one in the femoral group (0.7%).(3) Major procedural complication rates were similar 
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between superior versus femoral groups in contrast to the present study which identified significant 
differences between procedure related major complications including deaths in the femoral versus non-315 
femoral groups. This is likely to be explained by the fact that the vast majority of our femoral cases were 
performed as bailout procedures in cases where superior TLE had failed, therefore identifying them as a high-
risk group. However, we found the major procedure related complication rate including deaths was 0% where 
TLE was undertaken as a primary procedure in keeping with Bordachar et al. Our overall procedure related 
major complication rate of 1.9% and procedure related mortality rate of 0.3% is in line with the ELECTRa 320 
study (1.7% and 0.5% respectively),(2) the largest published experience of contemporary lead extraction, 
although the mean lead dwell time and number of leads extracted per case in the present study was higher 
compared to ELECTRa (7.27.2 vs. 6.45.4 years and 2.11.0 vs. 1.80.9 leads). In keeping with ELECTRa, we 
found that femoral extraction versus superior extraction via the original implant vein was associated with an 
approximately 3-fold higher rate of clinical failure 3.4% vs 1.1% (ELECTRa study OR 3.93).(2) Similarly, in 325 
ELECTRa a femoral approach was associated with a higher incidence of procedure related major 
complications including mortality (odds ratio of 3.6) without an increase in all-cause mortality(2) as in the 
present study. El-Chami et al. previously collated two registries to assess predictors and outcomes of the 
bailout femoral approach.(16) A total of 50/1080 (4.6%) patients required a bailout transfemoral lead 
extraction in their study compared to 104/1038 (10.0%) in the present study.(16) Patients undergoing bailout 330 
transfemoral extraction in our cohort had longer lead dwell times (11.8  9.6 vs 9.5  6.0 years), more leads 
extracted per procedure (2.8  1.3 vs. 2.0  1.0) and a distinctly lower clinical failure rate (3.8% vs. 24%) 
compared to their combined cohort.(16) These marked differences between our bailout transfemoral lead 
extraction cohort and that described by El-Chami most likely explains the higher procedural major 
complication and mortality rates in our cohort (10/104, 9.6% vs 0/50, 0%).(16) Whilst El-Chami et al. did not 335 
perform regression analysis to assess independent predictors of bailout transfemoral extraction, they did 
conclude from analysis of their outcomes similar findings to the present study that longer lead dwells times 
and greater number of leads extracted were significantly higher in the bailout femoral group compared to 
their non-femoral group.(16) Additionally, they found that infection indication was significantly higher in the 
bailout femoral group.(16) 340 
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Clinical importance 
In the vast majority of our cases, lead extraction was performed successfully and safely from the superior 
approach using the original implant veins with an overall procedure related mortality rate of 0.3%. 
Importantly, the current study highlights that in patients where an initial superior approach using the original 
implant veins has failed and bailout transfemoral extraction is required, there is a significant risk of procedure 345 
related major complications (9.6%) with the need for emergency thoracotomy (4.8%) but with low procedure 
related mortality rates (1%) and high clinical success rates (>96% of cases). This is likely to reflect good pre- 
and intra-procedural planning with use of a hybrid lab or cardiac operating room being more frequently used 
in the femoral group with a cardiothoracic surgeon present in case emergency thoracotomy was required.  
 350 
Due to the increased risk of procedure related major complications requiring an emergency thoracotomy in 
patients progressing to a bailout transfemoral approach, identifying these at-risk patients therefore appears 
critically important to facilitate better procedural planning to ensure the correct expertise are present during 
the procedure in order to minimize but also deal with procedure related major complications effectively. The 
current findings also underpin the need for adequate procedure location planning to identify high-risk cases 355 
that may require a bailout transfemoral procedure so that they are performed in a setting where emergency 
surgery can be performed immediately (in the cardiac hybrid lab) and that if this is undertaken the majority 
of patients will survive. It also highlights the need for operator training and experience in femoral snaring 
techniques which were required in 118/1052 (11.2%) of all patients requiring lead extraction in our institution. 
One could argue that if such risk factors are identified (long lead dwell time, multiple leads with an infectious 360 
indication mandating removal of all leads) that these cases should be performed in centres and by operators 
with appropriate training and experience in femoral snaring techniques. This is important as the use of 
femoral snaring techniques is likely to be become increasingly prevalent and important in the future with the 
advent of leadless pacing technologies which may require such snaring techniques to allow removal. When 
planning procedure location, lead dwell time and number of leads requiring extraction should be taken into 365 
account in addition to older age, systemic infection indication and renal impairment which we have 
previously demonstrated are independent predictors of 30-day mortality.(13) Currently in our institution, all 
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prospective lead extraction cases are discussed in a multi-disciplinary meeting involving cardiac surgeons 
with a risk stratification process to determine the manner and location of a TLE. 
 370 
Limitations 
The findings in our study are subject to inherent limitations with observational studies. However, one of the 
key strengths of this study being a single-centred experience is that it is an all comers prospectively collected 
registry for TLE with real-world outcome data which excludes any selection bias that may occur with multi-
centre trials. In addition, it is possible that there are unknown confounders and bias between operator 375 
management strategies and techniques employed given there was no formal standardized protocol for TLE. 
Furthermore, modification of TLE techniques and use of new equipment over the study period are not 
considered in the analysis. Patients undergoing surgical lead extraction were excluded from the TLE registry 
and therefore this analysis is not entirely representative of all patients requiring lead extraction. Predictors 
of bailout transfemoral extraction were identified, however, the exact cause and effect relationship remains 380 
speculative. Additionally, identifying data on abandoned leads would have allowed further analysis with 
regards to identifying predictors of bailout transfemoral lead extraction, however, this information was not 
available in our prospectively collected database. Abandoned leads in the setting of device infection would 
mandate their removal and therefore may have contributed to the increased failure rate of transvenous lead 
extraction from the superior approach, for example, due to prolonged lead dwell times. Furthermore, 385 
abandoned leads may also have been a driver of increased complications as reported in the recent ELECTRa 
registry sub-analysis on procedural outcomes associated with transvenous lead extraction in patients with 
abandoned leads.(17) The study was also not designed to compare the effect of different techniques, 
equipment and approaches on bailout transfemoral lead extraction and additional data are warranted to 
explore this further. Importantly, femoral extraction was only undertaken in patients where a superior 390 
approach via the original implant vein was initially unsuccessful (bailout procedure) or not feasible (due to 
intravascular leads). The risks of femoral extraction are likely to be biased by this and this may be a 
significantly lower risk procedure if it is performed in all-comers as a primary procedure. Moreover, the 
analysis does not include leads extracted via the internal transjugular approach as this is not routinely 
 16 
practiced at our institution and therefore this analysis is not entirely representative of all lead extraction 395 
techniques but rather focuses on the use of transfemoral approach as a bailout technique. 
 
Conclusion 
Bailout transfemoral lead extraction is associated with increased risk of 30-day procedure related major 
complications but not 30-day all-cause mortality. Prolonged lead dwell time and increased number of leads 400 
extracted were independent predictors for bailout transfemoral lead extraction. Such patients should be 
considered high risk of major complications and requiring emergency thoracotomy and therefore performed 
by high-volume lead extraction centres with experience in multiple approaches and techniques including 
experience with transfemoral lead extraction and cardiothoracic facilities immediately available.  
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procedures 525 
Procedural outcomes and clinical characteristics calculated on a total of 104 bailout transfemoral lead 
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aIf >1 major complication (including death) occurred for a single transvenous lead extraction procedure, only 
one major complication or death was counted when calculating the ‘procedure related major complication 530 
including procedure related death’ rate.  
 
bOne patient undergoing bailout transfemoral lead extraction had an intra-procedural and post-procedural 
major complication which are recorded separately but not double counted for the overall 30-day procedure 
related major complication. 535 
 
Figure 1: (A) Univariable analysis to determine variables associated with bailout transfemoral lead extraction (B) 
Multivariable analysis to determine independent predictors of bailout transfemoral lead extraction 
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Odds ratio for continuous variables represents the relative increased risk of endpoint per unit increase (e.g. per 540 
one year increase in time for lead dwell time). 
 
ICD = implantable cardioverter-defibrillator, LV = left ventricular, LVEF = left ventricular ejection fraction, CABG = 
coronary artery bypass graft surgery 
 
 
Figure 1: (A) Univariable analysis to determine variables associated with bailout transfemoral lead 
extraction (B) Multivariable analysis to determine independent predictors of bailout transfemoral lead 
extraction 
 
Odds ratio for continuous variables represents the relative increased risk of endpoint per unit increase (e.g. 
per one year increase in time for lead dwell time). 
 
ICD = implantable cardioverter-defibrillator, LV = left ventricular, LVEF = left ventricular ejection fraction, 




Tables and Figures 
 
Table 1: Device and lead characteristics 
 




Combined Group Totals 
(n=1052) 
CRT-Pacemaker 11/118 (9.3%) 52/934 (5.6%) 63/1048 (6.0%) 
CRT-Defibrillator 26/118 (22.0%) 190/934 (20.3%) 216/1048 (20.6%) 
Single chamber pacemaker 10/118 (8.5%) 71/934 (7.6%) 81/1050 (7.7%) 
Dual chamber pacemaker 38/118 (32.2%) 361/934 (38.7%) 399/1050 (38.0%) 
Single & dual chamber ICDs 33/118 (28.0%) 255/934 (27.3%) 288/1048 (27.5%) 
Bi-atrial pacemaker 0% 5/934 (0.5%) 5/1048 (0.5%) 






Right atrial pacing leads 88/318 (27.7%) 657/1864 (35.2%) 745/2182 (34.1%) 
Right ventricular pacing leads 132/318 (41.5%) 133/1864 (7.1%) 265/2182 (12.1%) 
Left ventricular coronary sinus leads 31/318 (9.7%) 191/1864 (10.2%) 222/2182 (10.2%) 
Single coil ICD lead 36/318 (11.3%) 188/1864 (10.1%) 224/2182 (10.2%) 
Dual coil ICD lead 31/318 (9.7%) 195/1864 (10.5%) 226/2182 (10.4%) 






Active 227/318 (71.4%) 1264/1864 (67.8%) 1491/2182 (68.3%) 
Passive 91/318 (28.6%) 600/1864 (32.2%) 691/2182 (31.7%) 
 
Device characteristics calculated on a total of 1052 procedures. Lead characteristics calculated on a 
total of 2182 leads extracted. 
 
CRT-cardiac resynchronization therapy 
ICD-implantable cardioverter-defibrillator 
  
Table 2: Patient demographics comparing femoral and non-femoral groups 
 







Mean age at extraction (years)  
standard deviation 
63.916.3 65.614.8 65.415.0 0.402 
Male 89/118 (75.4%) 686/934 (73.4%) 775/1052 (73.7%) 0.739 
Ischaemic heart disease 44/117 (37.6%) 356/893 (39.9%) 400/1010 (39.6%) 0.688 
Prior coronary artery bypass graft 
surgery 
16/117 (13.7%) 121/892 (13.6%) 137/1009 (13.6%) 1.000 
Previous valve repair or replacement 10/117 (8.5%) 88/891 (9.9%) 98/1008 (9.7%) 0.742 
Mean LVEF (%) 46.714.7 44.014.50 44.414.6 0.120 
Severe left ventricular systolic 
dysfunction (LVEF 35%) 
23/88 (26.1%) 207/632 (32.8%) 230/720 (31.9%) 0.225 
Diabetes mellitus 18/117 (15.4%) 134/884 (15.2%) 152/1001 (15.2%) 1.000 
Peripheral vascular disease 4/117 (3.4%) 37/884 (4.2%) 41/1001 (4.1%) 1.000 
Prior stroke 14/117 (12.0%) 65/886 (7.3%) 79/1003 (7.9%) 0.098 
Chronic obstructive pulmonary disease 13/117 (11.1%) 114/884 (12.9%) 127/1001 (12.7%) 0.659 
Renal impairment 22/118 (18.6%) 173/902 (19.2%) 195/1020 (19.1%) 1.000 
2 comorbidities 63/118 (53.4%) 492/933 (52.7%) 555/1051 (52.8%) 0.922 
3 comorbidities 41/118 (34.7%) 319/933 (34.2%) 360/1051 (34.3%) 0.918 
 
Patient demographics calculated on a total of 1052 procedures. Unknown values excluded from 
analysis denoted by varying denominators. 
 
LVEF-left ventricular ejection fraction 
  
Table 3: Procedural outcomes and clinical characteristics for femoral and non-femoral 
groups 
 









Systemic infection 22/118 (18.6%) 160/927 (17.3%) 182/1045 (17.4%) 0.700 
Local infection and/or erosion 49/118 (41.5%) 341/929 (36.7%) 390/1047 (37.2%) 0.314 
Combined infection 71/118 (60.2%) 501/927 (54.0%) 572/1045 (54.7%) 0.239 
Positive microbiology 60/116 (51.7%) 336/907 (37.0%) 396/1023 (38.7%) 0.003 
Vegetation visible on transthoracic or 
transesophageal echocardiogram 
17/93 (18.3%) 53/676 (7.8%) 70/769 (9.1%) 0.003 
Mean lead dwell time (years)  standard deviation 








Mean number of leads extracted per case  SD 









Hybrid Theatre (including OR) Procedure Location 33/118 (28.0%) 5/934 (0.5%) 38/1052 (3.6%) <0.001 
Powered sheath extraction required 90/118 (76.3%) 476/910 (52.3%) 566/1028 (55.1%) <0.001 
Clinical failure 4/118 (3.4%) 10/921 (1.1%) 14/1039 (1.3%) 0.064 
Emergency thoracotomy 5/118 (4.2%) 7/934 (0.7%) 12/1052 (1.1%) 0.007 
Details of 30-day procedure related major complications and deaths 
Procedure related major complications including 
procedure related deathsa  
10/118 (8.5%)b 10/934 (1.1%) 20/1052 (1.9%) <0.001 
 Intra-procedural 9/118 (7.6%) 9/934 (1.0%) 18/1052 (1.7%) <0.001 
 Post-procedural 2/118 (1.7%) 1/934 (0.1%) 3/1052 (0.3%) 0.035 
Procedure related deaths 1/118 (0.8%) 2/934 (0.2%) 3/1052 (0.3%) 0.300 
 Intra-procedural 0% 1/934 (0.1%) 1/1052 (0.1%) 1.000 
 Post-procedural 1/118 (0.8%) 1/934 (0.1%) 2/1052 (0.2%) 0.212 
Cardiac avulsion or tear 6/116 (5.2%) 4/929 (0.4%) 10/1045 (1.0%) <0.001 
Vascular avulsion or tear 5/116 (4.3%) 5/929 (0.5%) 10/1045 (1.0%) 0.002 
Flail tricuspid valve leaflet requiring intervention or 
surgery 
1/118 (0.8%) 0% 1/1052 (0.1%) 0.112 
Disseminated intravascular coagulation 0% 1/934 (0.1%) 1/1052 (0.1%) 1.000 
Stroke 2/116 (1.7%) 1/929 (0.1%) 3/1045 (0.3%) 0.034 
All-cause 30-day major complications including deaths 
All-cause 30-day major complications including 
deathsa 
13/118 (11.0%) 27/934 (2.9%) 40/1052 (3.8%) <0.001 
All-cause 30-day mortality 4/118 (3.4%) 19/934 (2.0%) 23/1052 (2.2%) 0.315 
Details of 30-day non-procedure related major complications including deaths 
Heart failure 0% 1/934 (0.1%) 1/1052 (0.1%) 1.000 
Sepsis with or without multi organ failure 1/118 (0.8%) 14/934 (1.5%) 15/1052 (1.4%) 0.716 
Respiratory arrest 1/118 (0.8%) 0% 1/1052 (0.1%) 0.112 
Arrhythmia 1/118 (0.8%) 2/934 (0.2%) 3/1052 (0.3%) 0.300 
30-day non-procedure related deaths 3/118 (2.5%) 17/934 (1.8%) 20/1052 (1.9%) 0.483 
 
Procedural outcomes and clinical characteristics calculated on a total of 1052 procedures. Unknown 
values excluded from analysis denoted by varying denominators. 
  
aIf >1 major complication (including death) occurred for a single transvenous lead extraction 
procedure, only one major complication or death was counted when calculating the ‘procedure related 
major complication including procedure related death’ rate.  
 
bOne patient in the Femoral group had an intra-procedural and post-procedural major complication 




Table 4: Breakdown of causes of all-cause 30-day Mortality 
 








Sepsis 2/4 (50.0%) 15/19 (78.9%) 17/23 (73.9%) 
Arrhythmia (ventricular 
fibrillation) 
1/4 (25.0%) 2/19 (10.5%) 3/23 (13.0%) 
Superior vena cava tear 0% 1/19 (5.3%) 1/23 (4.3%) 
End-stage heart failure 0% 1/19 (5.3%) 1/23 (4.3%) 
Pneumonia 1/4 (25.0%) 0% 1/23 (4.3%) 
 
Clinical records were reviewed to determine cause of death of patients who died within 30 days 
following lead extraction.  
  
Table 5: Demographics of patients undergoing bailout transfemoral lead extraction 
 
 
Demographics Bailout transfemoral lead 
extraction 
(n=104) 
Mean age at extraction (years)  standard deviation 63.916.1 
Male 79/104 (76.0%) 
Ischaemic heart disease 38/103 (36.9%) 
Prior coronary artery bypass graft surgery 15/103 (14.6%) 
Previous valve repair or replacement 9/103 (8.7%) 
Mean LVEF (%) 47.014.9 
Severe left ventricular systolic dysfunction (LVEF 35%) 19/78 (24.4%) 
Diabetes mellitus 17/103 (16.5%) 
Peripheral vascular disease 4/103 (3.9%) 
Prior stroke 14/103 (13.6%) 
Chronic obstructive pulmonary disease 12/103 (11.7%) 
Renal impairment 21/104 (20.2%) 
2 comorbidities 56/104 (53.8%) 
3 comorbidities 38/104 (36.5%) 
 
Patient demographics calculated on a total of 104 bailout transfemoral lead extraction procedures. 
Unknown values excluded from analysis denoted by varying denominators. 
 
LVEF-left ventricular ejection fraction 
  
Table 6: Procedural outcomes and clinical characteristics of bailout transfemoral lead 
extraction procedures 
 
Indications and Clinical features for Transvenous Lead Extraction Bailout transfemoral lead 
extraction 
(n=104) 
Systemic infection 16/104 (15.4%) 
Local infection and/or erosion 43/104 (41.3%) 
Combined infection 59/104 (56.7%) 
Positive microbiology 52/102 (51%) 
Vegetation visible on transthoracic or transesophageal 
echocardiogram 
13/82 (15.9%) 
Mean lead dwell time (years)  standard deviation 
Median lead dwell time (years) [IQR] 
11.89.6 
9.0 [4.3-16.4] 
Mean number of leads extracted per case  SD 




Hybrid Theatre (including operating room) Procedure Location 32/104 (30.8%) 
Powered sheath extraction required 81/104 (77.9%) 
Clinical failure 4/104 (3.8%) 
Emergency thoracotomy 5/104 (4.8%) 
Details of 30-day procedure related major complications and deaths 
Procedure related major complications including procedure 
related deathsa  
10/104 (9.6%) b 
 Intra-procedural 9/104 (8.7%) 
 Post-procedural 2/104 (1.9%) 
Procedure related deaths 1/104 (1.0%) 
 Intra-procedural 0/104 (0%) 
 Post-procedural 1/104 (1.0%) 
Cardiac avulsion or tear 6/103 (5.8%) 
Vascular avulsion or tear 5/103 (4.9%) 
Flail tricuspid valve leaflet requiring intervention or surgery 1/104 (1.0%) 
Stroke 2/103 (1.9%) 
All-cause 30-day major complications including deaths 
All-cause 30-day major complications including deathsa 12/104 (11.5%) 
All-cause 30-day mortality 3/104 (2.9%) 
Details of 30-day non-procedure related major complications including deaths 
Sepsis with or without multi organ failure 1/104 (1.0%) 
Arrhythmia 1/104 (1.0%) 
30-day non-procedure related deaths 2/104 (1.9%) 
 
Procedural outcomes and clinical characteristics calculated on a total of 104 bailout transfemoral lead 
extraction procedures. Unknown values excluded from the analysis denoted by varying denominators.  
 
aIf >1 major complication (including death) occurred for a single transvenous lead extraction 
procedure, only one major complication or death was counted when calculating the ‘procedure related 
major complication including procedure related death’ rate.  
 
bOne patient undergoing bailout transfemoral lead extraction had an intra-procedural and post-
procedural major complication which are recorded separately but not double counted for the overall 
30-day procedure related major complication. 
